The Role of Patient Engagement Programs Alongside Hub and SP
The pharmaceutical industry continues to make a clear commitment to pharma patient engagement, and the total market investment is expected to increase more than 15% by 2030, according to Grand View Research. However, biopharma companies face abandonment and persistency challenges when using a HUB-only approach to patient engagement. The barriers to medication adherence are complex and only begin with financial and access challenges. The HUB-only model falls short because it does not address the gaps that a well-designed patient engagement program can. A collaborative, parallel approach capitalizes on expertise and technology at all points of the patient journey, from time of prescription through to ongoing adherence.
Patient Engagement, HUB, and Specialty Pharmacy Programs Work as One
A collaborative, parallel approach are parts of a better whole when effectively employed. The time to start these interventions is early, right at prescription, and they should continue throughout therapy duration to enhance ongoing adherence.
This level of support features a single point of contact as a go-to, personal resource. Patients need a trusted, consistent resource to support them in a timely manner, which scripted, one-size-fits-all engagement models fail to do. Professionals such as Clinical Nurse Educators can provide information and holistic, emotional, and wellness support. Moreover, the patient receives personalized and dynamic health coaching. Through this process, a long-term, trusted relationship is built with patients.
Effective patient engagement programs also work directly with caregivers to provide and receive insight into individual patient challenges and can adapt throughout the therapy journey.
Advantages of Partnering with a Focused Patient Engagement Company
The collaborative model goes beyond current models of patient engagement. Working with a patient engagement partner to initiate such a program is highly advantageous. It allows the pharma company to stay focused on its expertise and avoid the trial and error of establishing new patient programs. This model is a core competency of VMS Biomarketing, using efficient models, tailoring what is needed, and specialized innovation to fit each situation, which has demonstrated a proven impact on results.
Benefits to Patients and Pharma
Delivering great patient engagement holds numerous benefits for both patients and pharma companies. For patients, the benefits include reduced day-to-day burdens in deciphering access, dosage, and how to integrate the therapies into their daily lives. This empowers the patient to be more active in the process and, subsequently, can lead to peace of mind. These are all factors in the most important benefit: better clinical outcomes.
Latest posts
From Logistics to Relationship: Reimagining Patient Engagement Through Empathy and Connection
Redefining the Patient Journey in the Age of DTC
A quiet revolution is reshaping how therapies reach patients — and it’s happening faster than anyone expected. The pharmaceutical industry is experiencing a transformative shift towards Direct-to-Consumer (DTC) models, driven by several legislative and regulatory changes.
Where Human Expertise Meets AI: Advancing Patient Engagement
Artificial intelligence (AI) has advanced rapidly in its ability to understand language and detect emotion, giving pharmaceutical manufacturers powerful tools to scale and customize patient engagement. But AI on its own can’t deliver the kind of empathetic support patients truly need.
Three Pillars of Rare Disease Support: Building an Essential Network
Discover the three essential pillars of rare disease support: medical expertise, community connections, and family engagement. Learn how integrating these elements creates comprehensive support networks for the 1 in 1,500 Americans affected by rare diseases.